2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 333

Pressure and Blood Flow Measurements in Efferent Lymphatics As Biomarkers of Arthritic Flare
Abstract Number: 1957

Prevalence and Associated Factors of Vitamin D Insufficiency and Deficiency in 4,793 Japanese Patients with Rheumatoid Arthritis
Abstract Number: 176

Prevalence and Associations of Hepatitis C Arthritis in Chronic Hepatitis C Virus Infection
Abstract Number: 2426

Prevalence and Characteristics of Sleep Problems in Rheumatoid Arthritis: A Systematic Review of the Literature
Abstract Number: 300

Prevalence and Clinical Significance of Hippocampal Atrophy in Childhood-Onset Systemic Lupus Erythematosus
Abstract Number: 1424

Prevalence and Clinical Significance of Severe Infection in Patients with Systemic Lupus Erythematosus: Preliminary Data From Relesser (Registry of lupus of the Spanish Society of Rheumatology)
Abstract Number: 562

Prevalence and Predictors of Significant Liver Fibrosis in Methotrexate Treated Rheumatoid and Psoriatic Arthritis Patients Using Transient Elastography (fibroscan)
Abstract Number: 1488

Prevalence and Risk Factors of Low Bone Mineral Density in Chinese Patients with Systemic Sclerosis: A Case-Control Study
Abstract Number: 2565

Prevalence of Anti-Neutrophil Cytoplasmic Antibodies in Infective Endocarditis: An Analysis of 109 Cases
Abstract Number: 1194

Prevalence of Anti-Peptidylarginine Deiminase Type 4 Antibodies in Rheumatoid Arthritis and Unaffected First-Degree Relatives in Indigenous North American Populations
Abstract Number: 374

Prevalence of Biologic Utilization Over Calendar Time Among Medicare Beneficiaries with Rheumatoid Arthritis
Abstract Number: 551

Prevalence of Enthesitis in Psoriatic Patients: Agreement Between Clinical and Power Doppler Ultrasonography Exploration and Its Implications for the Classification of Psoriatic Arthritis
Abstract Number: 2182

Prevalence of Fibromyalgia Is Increased in Primary Sjögren’s Syndrome Compared with SLE and Associated with Depression and Severe Vitamin D Deficiency
Abstract Number: 157

Prevalence of Gout Among Adults with Chronic Kidney Disease in the United States, 2009-10
Abstract Number: 1618

Prevalence of Inflammatory Sacroiliitis Assessed On MR Imaging of Inflammatory Bowel Disease: A Retrospective Study Performed On 186 Patients

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].